This is a preliminary report of an ongoing study to test the efficacy of intralesional injections of the anti viral dru g cidofov ir in adults with recurrent laryngeal papilloma s in whom mul tipl e other treatm ents ha ve previously failed.
Introduction
Laryngeal papillomas, which were origi nally described in the 17th ce ntury as "w arts in the throat," occur in two age gro ups: adults and yo ung children. Th ere is no distin ct difference in the histology of the disease betwe en these two gro ups of patient s. Laryngeal pap illom as are notoriously unpredictab le in their clinical beh avior , and treat- Laryngeal papillomas are ca used by an infection with hum an papillomaviru s (HPV). The mech ani sms of acquisition and tran smi ssion of HPV in patient s with laryngeal papill om as have not been determined, nor have the specific etiol ogic fact ors that pred ispose certain adult s to HPV . Currentl y, no medical or surgical cure exists, although palli ative interventions (e.g., laser ablation) are routinely employed. Alth ough so me cases of laryn geal papilloma regre ss ove r tim e, parti cularly around adolescence, others become lon g-term , chronic management probl em s that last for decades. In such cases , the lesions can undergo a malignant tran sformation i,2 or lead to invo lvement of the tracheopulmonary tree .
The antiviral medication cid ofovir was recently approved for the treatment of cytomegalov irus retinitis in patients with acquired immunodeficiency syndrome. The drug ' s efficacy has also been sugges ted in the treatment of esophage al papi llom as, as reported in one patient by Van Cut sem et al,' and in the treatm ent oflaryngea l papill omas in children and ad ults, as reported by Sn oeck et a1. 4 Both of these studies were unc ont rolled .
The purp ose of the phase IlIa study described in this report is to defin e the safe ty and efficacy of int ralesional inj ections of cidofov ir in adults with respiratory papill omatosis. Altho ugh this dru g ca n be administered intra venou sly, or possibl y in a nebuli zed form, it app ears that the safes t and most controlled meth od of dru g deli very is by local injection at the tumor site. Thi s is the rout e that is bein g used in this study.
Materials and methods
Thi s preliminary report describes the outcomes of the first The nasal turbinates are effectively reduced long-term in hyperplasia ( Fig.1 ).
APC permits non-contact, homogeneous and highly effective treatment of superficial lesions of the oral mucosa such as granuloma and leucoplakia ( Fig. 2 ).
APC's limited penetration depth offers maximum protection against perforation in treatments of papillomatosis ( Fig. 3 ).
Telangiectatic lesions in the nasal mucosa can be treated as well as lesions in th e skin and mucosa of the lips and oral cavity ( Fig. 4 ). three patients who entered the study. Following enrollrnent , each of the three patients underwent endoscopy in the surgical suite . Tracheobronchial and bronchial examinations were performed, and al1lesions were treated by inject ing cidofovir into each of the papillomas and the surrounding mucosa. Cidofovir (Vistide; Gilead Sciences) is a new compound, 1-[(S)-3-hydroxy-2-phosphonomethoxy)propyl]cytosine dihydrate, that is effective in the destruction of a broad range of DNA viruses. The maximum total volume of drug administered during the endoscopic procedure was determined by the number of lesions and the size of the patient's airway. All three patients received the medication within the bounds of current Food and Drug Administration dosing recommendations (5 mg/kg for intravenous use) and well below any levels that have been reported to lead to toxicity. The concentration of cidofovir was 4.17 mg/ml, and each patient received a total dose of 5 to 10m!. The approximate volume injected into each wart was 0.2 to 0.5 m!. This amount was determined by direct observation of the amount necessary to blanch each wart. The maximum amount of medication any patient received did not exceed I mg/kg. One to 2 weeks following each administration of cidofovir, patients were evaluated by rigid"and flexible laryngoscopy at the George Washington University Voice Treatment Center. Lesions were reinfiltrated with cidofovir in the oper ating room every 2 to 4 weeks. When papiIIomas were no longer seen on endoscopy, cidofovir was administered one more time at the site of the lesion, and a biopsy was taken. When lesions were stil1 not visible during two consecutive rigid laryngoscopic office examinations, treatment was suspended and the patients continued to be evaluated by rigid or flexible laryngoscopy every 3 months. When lesions reappeared, cidofovir injections resumed and were administered every 2 weeks, with endoscopic fol1owup, until they were again no longer seen on endoscopy.
All patients were seen forfollowup at 3, 6, 12, 18, and 24 months after enrollment, regardless of the timing of their cidofovir administration.
Results
Patient til. In June 1989, a then-26year-old physician and professional singern oted persistent hoarseness following a recording session. He was subsequently diagnosed with laryngeal papilloma. His papillomas were positive for HPV types 6 and I I. Tumors were present on the false vocal folds, the true folds, and the subglottis. Over the years, this patient underwent 65 excisions with a CO 2 laser, but the disease did not resolve. Over the next several years, he underwent treatment at various times with interferon alpha-n I, thymosine, isoprinosine, and photodynamic therapy.
Eventually, he was treated with seven sessions of cidofovir intralesional injections over a 6-month period during 1994 and 1995 in Belgium. He did wel1 until May 1998, when a recurrence was noted on the anterior vocal folds. He then came to The George Washington University Medical Center and received two more injections and achieved a complete response. He remained lesion-free until late 1999, when he experienced a minor recurrence, which quickly responded to additional injections.
Patient #2. A 63-year-old aerospace engineer came to us in September 1997 with a 30-plus-year history of recurring laryngeal papil1omas. He had undergone at least 65 direct laryngoscopies and sharp and CO 2 laser excisions. His papillomas were positive for HPV types 6 and I I. Over the years , he required two tracheotomies.
After he entered this study, he received 15 injections of cidofovir. Initially, the injections were administered every 2 to 4 weeks, but the interval was gradually lengthened to every 3 months. Treatment was discontinued when his larynx appeared to be tumor-free on rigid laryngoscopy (figure I) . Three months later, he experienced the simul- has been effective, but as yet not curative. Th e concentration of cidofovir was relatively mode st (4.17 mg/ml ). As our study progresses, we will incre ase the concentration to 6.25 mg/ml, which we hop e will lead to a more perm anent respons e. There is some concern regarding cido fovir ' s potential carcinogenic effect. In the origin al group studied by Snoeck et ai, three of 17 patient s had squamous cell carcinoma in situ, but two of them had already developed it prior to treatment.' All three were smokers.
The advantages of intralesional cidofovir treatment are important. First, unlik e other treatments, the injections do not appear to injure the larynx. Therefore, even anterior commissure lesions can be inje cted without fear of causing web formation . Second, injections are safer than laser therap y, which carries a risk offire and a risk of the virus spreading from the laser' s vapor plume to the patient 's lowe r tracheobronchi al tree or to operating room personnel. Th ird, injection therapy requires far less time under anesthesia than does excision. Finally, patients report that they experience less postoperative discomfort.
It appears that intr ale sional injections of cido fovir have the potential to be an important adjunct to the treatm ent of laryngeal papilloma. With furth er refinement of the dosage and frequ ency schedules, it could in time become a princ ipal therapy for this disease.
Discussion
After a series of intralesional cidofovir injections, which were not supplemented by any other ther apy, all three patients experienced a complete resoluti on of their papillomas on visual examinati on. Eventually, however, all three patients ex perienced a minor recurrence (pati ent # I after 18 month s, patient #2 after 3 month s, and patient #3 after 6 months) . All these recurrences responded to further intralesion al inje ctions.
Thus far, the treatm ent of the three adults in our study taneous development of several small areas of recurrence, and intralesional injecti ons of cidofovir were resumed with good results. No other treatment has been necessary. Patient #3. A 30-y ear-old executive was referred to us for treatment of laryngeal papillomas. His disease involved both vocal folds and the anterior commi ssure, which had been unsucc essfully treated with CO 2 laser ablations. His papillomas were positive for HPV types 6 and II . Followin g intralesional cido fovir injections over a 4-month period, the disease appeare d to have resolved completely (figur e 2). A biopsy was taken of the laryngeal mucosa where the papillomas had been , and it was reported and normal on light micro scopy . Six month s after his last injection, the man was noted to have a recurrence on one vocal fold . He underwent micro laryngoscopy with injection, and has since experienced an apparent resolution of the remaining lesion . 
